-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$59.2529.54% Upside
Corcept Therapeutics Incorporated Frequently Asked Questions
-
What analysts cover Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated has been rated by research analysts at Truist Financial, Canaccord Genuity, Piper Sandler, H.C. Wainwright in the past 90 days.